News and Events banner photo

News & Events
Stay Informed with Industry Insights and Follow Our Progress

Scientist in background holding filled vial in foreground

Filter

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder CancerCompany NewsNews HighlightRAG-01

Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer

Nantong, China – March 19, 2026 – Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small…
March 19, 2026
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALSCompany NewsHomepage NewsNews HighlightRAG-17Uncategorized

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

Nantong, China – January 13, 2026 – Ractigen Therapeutics is pleased to announce that the…
January 13, 2026
RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)Company NewsHomepage NewsPresentations

RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)

Event: American Academy of Neurology (AAN) 2025 Annual Meeting (San Diego) View Abstract View News:…
April 9, 2025
Ractigen’s RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025Company NewsHomepage NewsNews HighlightRAG-01

Ractigen’s RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025

NANTONG, China, and MELBOURNE, Australia, March 24, 2025 – Ractigen Therapeutics, a clinical-stage biopharmaceutical company…
March 24, 2025
Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking AwardCompany NewsHomepage NewsNews Highlight

Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award

NANTONG and SUZHOU, China, Dec. 30, 2024 — Ractigen Therapeutics proudly announces that its Founder…
December 31, 2024
Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALSCompany News

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

NANTONG and SUZHOU, China, Dec. 24, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated…
December 24, 2024